Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 윤채옥 | - |
dc.date.accessioned | 2019-12-05T16:43:25Z | - |
dc.date.available | 2019-12-05T16:43:25Z | - |
dc.date.issued | 2018-02 | - |
dc.identifier.citation | CURRENT CANCER DRUG TARGETS, v. 18, no. 2, page. 139-152 | en_US |
dc.identifier.issn | 1568-0096 | - |
dc.identifier.issn | 1873-5576 | - |
dc.identifier.uri | http://www.eurekaselect.com/150343/article | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/117658 | - |
dc.description.abstract | Novel treatment modalities are rapidly advancing toward clinical use as many malignant cancers still remain incurable. Adenovirus (Ad) in particular has been extensively researched as a promising alternative to conventional cancer therapy in the past decades. Although Ad has demonstrated promising therapeutic outcome and cancer specificity in preclinical models, its therapeutic efficacy in clinical trials is still insufficient due to several drawbacks such as rapid clearance of viral particles by host immune response, induction of acute inflammatory response, and hepatotoxicity. In this regard, combination of Ad with other cancer treatment modalities, such as chemotherapy, radiotherapy, or immunotherapy, can be an effective strategy to overcome the limitations of Ad. Cancer-specific and effective expression of multifunctional therapeutic genes by Ad can enhance the therapeutic profile of other treatment modalities, making it a logical candidate for combination therapy to combat malignant tumors. | en_US |
dc.description.sponsorship | This work was supported by grants from the National Research Foundation of Korea (2015R1A2A1A13027811, 2016M3A9B5942352, 2013M3A9D3045879; Dr. C-O Yun). | en_US |
dc.language.iso | en_US | en_US |
dc.publisher | BENTHAM SCIENCE PUBL LTD | en_US |
dc.subject | Combination therapy | en_US |
dc.subject | adenovirus | en_US |
dc.subject | oncolytic adenovirus | en_US |
dc.subject | chemotherapy | en_US |
dc.subject | cancer | en_US |
dc.subject | immunotherapy | en_US |
dc.subject | radiotherapy | en_US |
dc.title | Emergence of Ad-Mediated Combination Therapy Against Cancer: What to Expect? | en_US |
dc.type | Article | en_US |
dc.relation.no | 2 | - |
dc.relation.volume | 18 | - |
dc.identifier.doi | 10.2174/1568009617666170222123406 | - |
dc.relation.page | 139-152 | - |
dc.relation.journal | CURRENT CANCER DRUG TARGETS | - |
dc.contributor.googleauthor | Hong, JinWoo | - |
dc.contributor.googleauthor | Yun, Chae-Ok | - |
dc.relation.code | 2018012173 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF ENGINEERING[S] | - |
dc.sector.department | DEPARTMENT OF BIOENGINEERING | - |
dc.identifier.pid | chaeok | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.